
CLAIMS

1. A compound of formula (II), a stereoisomer thereof or a pharmaceutically acceptable salt thereof,



(II)

wherein,

 is selected from the group consisting of a single bond and a double bond;

X is selected from the group consisting of CR_3 and N;

Y is selected from the group consisting of CR_1 and C;

L_1 is selected from the group consisting of a single bond and $-(CR_8R_9)_n$;

L_2 is selected from the group consisting of a single bond, $-CR_8R_9-$ and =CH-;

L_1 and L_2 are not single bonds at the same time;

when L_2 is selected from a single bond,  is selected from a single bond;

L_3 and L_4 are each independently selected from $-CR_8R_9-$;

n is 1 or 2;

R_1 is selected from the group consisting of H, D, F, Cl, Br, I and C_{1-3} alkyl, wherein the C_{1-3} alkyl is optionally substituted with 1, 2 or 3 R_a, and when L_2 is selected from =CH-, R_1 is absent;

R_2 and R_{10} are each independently selected from the group consisting of H, F, Cl, Br, I and C_{1-3} alkyl, wherein the C_{1-3} alkyl is optionally substituted with 1, 2 or 3 R_b;

R_3 is selected from the group consisting of H, F, Cl, Br, I, CN and C_{1-3} alkyl, wherein the C_{1-3} alkyl is optionally substituted with 1, 2 or 3 R_c;

R_4 is selected from the group consisting of H and F;

R_5 is selected from the group consisting of H and C_{1-3} alkyl, wherein the C_{1-3} alkyl is optionally substituted with 1, 2 or 3 R_d;


R_6 and R_7 are each independently selected from the group consisting of H and D;

R_8 and R_9 are each independently selected from the group consisting of H, F, Cl, Br, I and C_{1-3} alkyl, wherein the C_{1-3} alkyl is optionally substituted with 1, 2 or 3 R_e;

R_a, R_b, R_c, R_d, and R_e are each independently selected from the group consisting of F, Cl, Br, I, OH, CN, NH_2, COOH, $C(=O)NH_2$, CH_3, CH_3CH_2, CF_3, CHF_2, CH_2F, $NHCH_3$ and $N(CH_3)_2$;

the 3-8 membered heterocycloalkyl comprises 1, 2, 3 or 4 atoms or groups of atoms each independently selected from the group consisting of O, N, S and NH.

2. The compound, the stereoisomer thereof or the pharmaceutically acceptable salt thereof according to claim 1, selected from formula (II-1)



(II-1) , wherein

R_1, R_2, X, R_4, R_5, R_6, R_7, R_{10}, L_1, L_2, L_3 and L_4 are as defined in claim 1.

3. The compound, the stereoisomer thereof or the pharmaceutically acceptable salt thereof according to claim 1, wherein R_1 is selected from the group consisting of H, D, F and CH_3.

4. The compound, the stereoisomer thereof or the pharmaceutically acceptable salt thereof according to claim 1, wherein R_2 and R_{10} are each independently selected from the group consisting of H and F.

5. The compound, the stereoisomer thereof or the pharmaceutically acceptable salt thereof according to claim 1, wherein R_3 is selected from the group consisting of H, F, CN, Cl and CF_3; preferably, R_3 is selected from the group consisting of H and F.

6. The compound, the stereoisomer thereof or the pharmaceutically acceptable salt thereof according to claim 1, wherein R_5 is selected from the group consisting of H, methyl, ethyl, propyl and isopropyl, wherein the methyl, ethyl, propyl and isopropyl are optionally substituted with 1, 2, or 3 R_d; preferably, R_5 is selected from the group consisting of H, methyl,  and isopropyl.










7. The compound, the stereoisomer thereof or the pharmaceutically acceptable salt thereof according to claim 1, wherein L_1 is selected from the group consisting of a single bond and $-CR_8R_9-$.









8. The compound, the stereoisomer thereof or the pharmaceutically acceptable salt thereof according to claim 1, wherein L_1 is selected from $-CR_8R_9-$, and L_2 is selected from $-CR_8R_9-$.



9. The compound, the stereoisomer thereof or the pharmaceutically acceptable salt thereof according to claim 1, wherein L_1 is selected from $-CR_8R_9-$, and L_2 is selected from a single bond.







10. The compound, the stereoisomer thereof or the pharmaceutically acceptable salt thereof according to claim 1, wherein R_8 and R_9 are each independently selected from the group consisting of H and F; preferably, both R_8 and R_9 are selected from H, or one of R_8 and R_9 is selected from H and the other is selected from F.





11. The compound, the stereoisomer thereof or the pharmaceutically acceptable salt thereof according to claim 1, wherein R_6 and R_7 are both H.

12. The compound, the stereoisomer thereof or the pharmaceutically acceptable salt thereof according to claim 1, wherein the structural unit  is selected from the group consisting of , , , , , ,  and .


13. The compound, the stereoisomer thereof or the pharmaceutically acceptable salt thereof according to claim 1, wherein the structural unit  is selected from the group consisting of , , , , ,  and .


14. The compound, the stereoisomer thereof or the pharmaceutically acceptable salt thereof according to claim 1, wherein the structural unit  is selected from .

15. The compound, the stereoisomer thereof or the pharmaceutically acceptable salt thereof according to claim 1, wherein the structural unit  is selected from the group consisting of , , , ,  and .


16. The compound, the stereoisomer thereof or the pharmaceutically acceptable salt thereof according to claim 1, wherein the structural unit  is selected from the group consisting of ,  and .


17. A compound of a formula below, a stereoisomer thereof or a pharmaceutically acceptable salt thereof, selected from the group consisting of






18. The compound, the stereoisomer thereof or the pharmaceutically acceptable salt thereof according to claim 17, selected from the group consisting of







19. A pharmaceutical composition comprising a therapeutically effective amount of the compound, the stereoisomer thereof or the pharmaceutically acceptable salt thereof according to any one of claims 1-18 and a pharmaceutically acceptable carrier.

20. Use of the compound, the stereoisomer thereof or the pharmaceutically acceptable salt thereof according to any one of claims 1-18 in preparing a medicament for use in treating a tumor or a cancer.